Generic in Medical Technology
Navigation Links
Generic in Medical Technology
... of people who had switched from a brand-name to a generic AED, while side effects increased for 49 percent ... for 15 percent of those who had switched from a generic to brand AED, while side effects increased for 18 ... problems after switching between different generic formulations of an AED.
"Brand names of ...
... April 27 /PRNewswire-USNewswire/ -- Men taking generic drugs may be more likely to have less effective ... Urological Association (AUA) showing that generic substitutes for alpha blockers and 5-alpha ... with an average age of 64, who were switched to generic alternatives by their primary care physician or ...
... mg, and 10 mg/325 mg strengths. The Office of generic Drugs, U.S. Food and Drug Administration, has ... RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. ... producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals ...
... was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals. In an analysis of data pooled ... development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on ...
... New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company believes that Cobrek is the ... healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...
... risks that may arise from the outcome of any appeal, the adverse impact of generic product distributed into the market by Apotex, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those ...
... initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa (R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum (R) (olsalazine sodium) patients were ...
... initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... as well as the company's value." Fluidosomes-tobramycin combines the companys proprietary Fluidosomes technology with the well-established generic drug tobramycin. Utilising synthetic liposomes containing tobramycin, a standard nebulizer delivers the drug directly to the endobronchial sites of ...
... Inc. Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical). In the U.S., the ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... CEO of Pharmacyclics noted, "We appreciate the vote of confidence by the principals of PBG, all extremely successful biotech, pharmaceutical and/or generic drug industry executives who have separately built three billion dollar plus companies. We are in active communication with the principals of PBG ...
... April 27 /PRNewswire-USNewswire/ -- Men taking generic drugs may be more likely to have less effective ... Urological Association (AUA) showing that generic substitutes for alpha blockers and 5-alpha ... with an average age of 64, who were switched to generic alternatives by their primary care physician or ...
ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
... (FDA) of comments on FDA's Office of generic Drugs' (OGD) December 2008 draft guidance to establish the bioequivalence (BE) of generic copies of Vancocin(R) (vancomycin hydrochloride ... to determine bioequivalence, provided that the generic product has the same inactive ingredients (Q1) ...Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
... Since major pharmacy retailers are promoting generic drug programs, patients may find a more ... formulations may cost more compared to the generic medications, so it is important for patients to discuss generic options with their dermatologist," said Dr. ...Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
... ), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the ... is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented ... strategy on the development of first-to-market generic and innovative pharmaceuticals, and has ...Watson Launches Generic Biaxin(R) XL
... Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R) XL, which is ... September 2007, Biaxin(R) XL and its generic equivalents had total U.S. sales of approximately ... markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth ...... mg, and 10 mg/325 mg strengths. The Office of generic Drugs, U.S. Food and Drug Administration, has ... RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. ... producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals ...
... was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals. In an analysis of data pooled ... development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on ...
... New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company believes that Cobrek is the ... healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...
New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability
... hydrochloride developed and marketed by Watson (NYSE: WPI ), a leader in generic and specialty branded pharmaceuticals. Because the active ingredient in ... development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on ...PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
... - Ataluren designated as generic name for PTC124 - SOUTH PLAINFIELD, N.J., Feb. 3 /PRNewswire/ -- PTC ... The company also announced today that PTC124 has been issued the generic name, ataluren. (Logo: ...Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
... of Mutual, Mylan and Impax requesting approval to manufacture and sell generic versions of DORYX 100 and 75 mg delayed-release tablets prior to the ... industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to ...ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
... and advanced or metastatic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million. Navelbine and its generic equivalents are often associated with injection site reactions, including ...... risks that may arise from the outcome of any appeal, the adverse impact of generic product distributed into the market by Apotex, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those ...
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
... or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million. "Completing ... is a crossover comparison of ANX-530 and Navelbine, also available as generic vinorelbine, with a primary endpoint of pharmacokinetic equivalence of ...Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
... this treatment available to the rest of the world, or license it out to a generic drug manufacturer, such as Cipla, which already produces a generic version in India, that will. In the instances where the registration ...... initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
... Inc. Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or ...... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa (R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum (R) (olsalazine sodium) patients were ...
... initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
Jubilant Enters Research Collaboration With AstraZeneca
... (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these ...... as well as the company's value." Fluidosomes-tobramycin combines the companys proprietary Fluidosomes technology with the well-established generic drug tobramycin. Utilising synthetic liposomes containing tobramycin, a standard nebulizer delivers the drug directly to the endobronchial sites of ...
Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
... 200,000 people. This provides Oasmia with seven year market exclusivity on the indication when the pharmaceutical is approved. There is no direct generic competition during the period and FDA often provides technical and financial assistance to expedite and optimize drug development. The ...Strativa Pharmaceuticals Provides Product Pipeline Update
... information, please visit www.strativapharma.com . About Par Pharmaceutical Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com . ...... Inc. Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical). In the U.S., the ...
... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...
Schering-Plough Announces Results of the Early ACS Trial
... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
... About Endo Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of ...... CEO of Pharmacyclics noted, "We appreciate the vote of confidence by the principals of PBG, all extremely successful biotech, pharmaceutical and/or generic drug industry executives who have separately built three billion dollar plus companies. We are in active communication with the principals of PBG ...
Other ContentsmaniamaniamaniamaniamammogrammammogrammandibledepressivedepressivedepressivedepressivemarrowmarrowmarrowmarrowmarrowmarrowmarrowmarrowmanicmanicmanicsyrupsyrupsyrupmapleOther TagsoxygeoxygeoxygeTASS
(Date:11/23/2009)...s that a common oral bacterium may exacerbate auto...al, "Unique Lipids from a Common Human Bacterium R...hancing Autoimmunity," appears in the December 200... Multiple sclerosis (MS), a disease where the imm...cts nearly 1 in 700 people in the United States. ...
(Date:11/23/2009)...ailable for the H1N1 virus has been sent to vaccin...ination marks the first time vaccine has been sent..., Iowa State University,s Hank Harris, professor ...er and has been shipping preventive doses to swine...l weeks., The latest vaccines were shipped to a ...
(Date:11/23/2009)...E and USDA study concluded that 50 million U.S. ac...re could be converted from current uses to the pro... from which biomass could be harvested for use as ...n of a perennial grass monoculture from which subs... is expected to require nitrogen fertilizer. , A...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2Child Care Centers Throughout Mexico Being Crucified Unjustly Says Interchildren Inc 52045 1Child Care Centers Throughout Mexico Being Crucified Unjustly Says Interchildren Inc 52045 2Senators Baucus and Grassley Statement Regarding Physician Hospitals Despicable 52040 1Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 1Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 2Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 3(Date:11/27/2009)...ealth™ announced today that Spectrum Health ...d Enterprise orthopedic templating solution and it... (PRWEB) November 27, 2009 -- Voyant...h (Grand Rapids, Michigan) has licensed its Trauma...its TraumaCad Extend workflow solution, to allow i...
(Date:11/27/2009)...st manufacturers who use medical load cells at the...llars by bringing in technology partner Flintec ea...ro-active medical manufacturers are calling in Fli...ir projects, ensuring that progress will not be co...lly outdated technology. , ...
(Date:11/26/2009)...ewswire/ -- With cold and flu season upon us, it,s... to control the spread of infections and avoid ill...eep ourselves healthy, but to avoid transmitting i..., CIC (certified in infection-control), nursing di...th at Hospital for Special Surgery (HSS) in Manhat...
(Date:11/26/2009)... of Americans living with diabetes will nearly dou...million in 2034. Over the same period, spending on...lion to $336 billion, even with no increase in the...niversity of Chicago report in the December issue ...iabetes covered by Medicare will rise from 8.2 mil...
(Date:11/26/2009)...y can lead to strains or worse , , THURS...ing wrong with stuffing your turkey full to bursti...th your suitcase as you pack for holiday trips. ,... U.S. hospital emergency rooms, doctors, offices, ...elated injuries, such as muscle strains, pulls and...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[0] Diabetes cases to double and costs to triple by 2034[2] Pack Right for the Holidays to Avoid the ER
oxygeAttributesParitymarathonersAbellHurdlesaddictionsSanitizedInnatelyTASSHemodialysisRediscoveredYagnaNeonatology
Other Tagsvariable 2variable 3rated 2rated 3rated 4rated 5rated 6latest 2latest 3latest 4latest 5latest 6latest 7latest 8latest 9latest 10
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |